Voyager Therapeut Cmn (VYGR) 13.71 $VYGR Voyage
Post# of 273254
Posted On: 09/21/2016 9:13:52 AM
Voyager Therapeut Cmn (VYGR) 13.71 $VYGR
Voyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
GlobeNewswire - Thu Sep 15, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced a co-exclusive worldwide license agreement with the California Institute of Technology (Caltech) related to novel adeno-associated virus (AAV) capsids. The license agreement covers all fields of use and includes novel AAV capsids that have demonstrated enhanced blood-brain barrier penetration for the potential treatment of CNS diseases following systemic administration of an AAV gene therapy vector.
VYGR: 13.71 (-0.04)
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington's Disease
GlobeNewswire - Mon Sep 12, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS) today announced a research collaboration with CHDI Foundation, Inc. (CHDI) to advance Voyager's VY-HTT01 program, an adeno-associated virus (AAV)-mediated gene-silencing therapy for Huntington's disease. The collaboration builds upon a previous collaboration between CHDI and Sanofi Genzyme and includes funding from CHDI to help support preparation for and filing of an investigational new drug application, as well as completion of a Phase 1 clinical trial. CHDI will be reimbursed for its support of Voyager's program upon VY-HTT01 achieving certain commercial milestones.
VYGR: 13.71 (-0.04)
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
GlobeNewswire - Thu Aug 11, 6:05AM CDT
VY-AADC01 Phase 1b Study for Advanced Parkinson's Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016
VYGR: 13.71 (-0.04)
Why Earnings Season Could Be Great for Voyager Therapeutics (VYGR)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:45AM CDT
Voyager Therapeutics (VYGR) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
VYGR: 13.71 (-0.04)
Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease
GlobeNewswire - Tue Aug 09, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced dosing of the first patient in the third cohort of the ongoing Phase 1b open-label trial of VY-AADC01 in patients with advanced Parkinson's disease following a recent meeting of the trial's data and safety monitoring board.
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Host Second Quarter 2016 Investor Update Call
GlobeNewswire - Thu Aug 04, 9:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its second quarter 2016 investor update conference call and live webcast scheduled for Thursday, August 11, 2016 at 8:30 a.m. EDT.
VYGR: 13.71 (-0.04)
Voyager (VYGR) Looks Good: Stock Adds 6.8% in Session
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:00AM CDT
Voyager Therapeutics, Inc. (VYGR) was a big mover last session, as the company's shares rose nearly 7% on the day.
VYGR: 13.71 (-0.04), AMPH: 21.26 (+2.26)
Voyager Therapeutics Provides First Quarter 2016 Investor Update
GlobeNewswire - Thu May 12, 6:00AM CDT
Enrollment Completed in 2 Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 11, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Host First Quarter 2016 Investor Update Call
GlobeNewswire - Thu May 05, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its first quarter 2016 investor update call before the open of the U.S. financial markets on Thursday, May 12, 2016. Voyager management will host a conference call and live audio webcast at 8:30 a.m. ET the same day.
VYGR: 13.71 (-0.04)
Voyager Therapeutics Highlights Programs in Parkinson's Disease and ALS; Announces Expansion of CNS Pipeline at R&D Day
GlobeNewswire - Fri Apr 29, 7:00AM CDT
Top-Line Proof-of-Concept Clinical Data for Parkinson's Disease Program (VY-AADC01) Remains on Track for the Fourth Quarter of 2016
VYGR: 13.71 (-0.04)
Voyager Therapeutics (Nasdaq: VYGR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Mon Apr 25, 10:12AM CDT
What:
VYGR: 13.71 (-0.04), NDAQ: 69.62 (-0.18)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 13.71 (-0.04), OMED: 11.61 (-0.01), GSK: 42.93 (-0.13), BMY: 56.00 (+0.44), CELGZ: 1.20 (unch)
Voyager Therapeutics to Host R&D Day and Webcast on April 29, 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that the Company will host an R&D Day on Friday, April 29, 2016, from 8:30 a.m. - 11:00 a.m. ET in New York City.
VYGR: 13.71 (-0.04)
Voyager Therapeutics (VYGR) Jumps: Stock Rises 13.9%
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:15AM CDT
Voyager Therapeutics, Inc. (VYGR) shares rose almost 14% in the last trading session.
VYGR: 13.71 (-0.04), AMPH: 21.26 (+2.26)
Voyager Therapeutics Promotes Jeff Goater to Chief Financial Officer
GlobeNewswire - Tue Feb 02, 5:00PM CST
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former senior vice president of finance and business development, to chief financial officer. In this new role, Mr. Goater will be responsible for overseeing the company's financial strategy and planning, investor and public relations, corporate operations and business development.
VYGR: 13.71 (-0.04)
ProMIS Neurosciences Announces Formation of Prestigious Scientific Advisory and Business Advisory Boards
PRWeb - Tue Jan 26, 6:06AM CST
ProMIS™ Neurosciences, dedicated to development of precision medicine therapeutics for neurodegenerative diseases is pleased to announce the formation of its two key advisory boards to accelerate company development. ProMIS' first products will focus on more effective treatment of Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS). ProMIS Neurosciences is currently in the process of identifying and validating epitopes specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease.
VYGR: 13.71 (-0.04)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 91.69 (+0.43), BMRN: 97.95 (-0.16), VYGR: 13.71 (-0.04), RPTP: 8.97 (unch), KNMD: (), SGMO: 4.62 (-0.08), BCLI: 2.52 (unch), CUR: 0.32 (+0.01)
Voyager Therapeutics Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Dec 17, 3:15PM CST
Initial public offering raised $72.7 million in net proceeds
VYGR: 13.71 (-0.04)
5 Biggest Losers from the Fed Rate Hike
Swarup Gupta - Zacks Investment Research - Thu Dec 17, 12:07PM CST
While markets greeted the news with cheer, worries can be felt below the surface.
MG: 24.09 (-0.21), CXO: 122.77 (-1.25), VYGR: 13.71 (-0.04), EGN: 52.27 (-0.41), SM: 33.24 (-1.31)
Voyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
GlobeNewswire - Thu Sep 15, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced a co-exclusive worldwide license agreement with the California Institute of Technology (Caltech) related to novel adeno-associated virus (AAV) capsids. The license agreement covers all fields of use and includes novel AAV capsids that have demonstrated enhanced blood-brain barrier penetration for the potential treatment of CNS diseases following systemic administration of an AAV gene therapy vector.
VYGR: 13.71 (-0.04)
Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntington's Disease
GlobeNewswire - Mon Sep 12, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS) today announced a research collaboration with CHDI Foundation, Inc. (CHDI) to advance Voyager's VY-HTT01 program, an adeno-associated virus (AAV)-mediated gene-silencing therapy for Huntington's disease. The collaboration builds upon a previous collaboration between CHDI and Sanofi Genzyme and includes funding from CHDI to help support preparation for and filing of an investigational new drug application, as well as completion of a Phase 1 clinical trial. CHDI will be reimbursed for its support of Voyager's program upon VY-HTT01 achieving certain commercial milestones.
VYGR: 13.71 (-0.04)
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
GlobeNewswire - Thu Aug 11, 6:05AM CDT
VY-AADC01 Phase 1b Study for Advanced Parkinson's Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016
VYGR: 13.71 (-0.04)
Why Earnings Season Could Be Great for Voyager Therapeutics (VYGR)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:45AM CDT
Voyager Therapeutics (VYGR) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
VYGR: 13.71 (-0.04)
Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease
GlobeNewswire - Tue Aug 09, 6:05AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced dosing of the first patient in the third cohort of the ongoing Phase 1b open-label trial of VY-AADC01 in patients with advanced Parkinson's disease following a recent meeting of the trial's data and safety monitoring board.
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Host Second Quarter 2016 Investor Update Call
GlobeNewswire - Thu Aug 04, 9:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its second quarter 2016 investor update conference call and live webcast scheduled for Thursday, August 11, 2016 at 8:30 a.m. EDT.
VYGR: 13.71 (-0.04)
Voyager (VYGR) Looks Good: Stock Adds 6.8% in Session
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:00AM CDT
Voyager Therapeutics, Inc. (VYGR) was a big mover last session, as the company's shares rose nearly 7% on the day.
VYGR: 13.71 (-0.04), AMPH: 21.26 (+2.26)
Voyager Therapeutics Provides First Quarter 2016 Investor Update
GlobeNewswire - Thu May 12, 6:00AM CDT
Enrollment Completed in 2 Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson's Disease
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Wed May 11, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:
VYGR: 13.71 (-0.04)
Voyager Therapeutics to Host First Quarter 2016 Investor Update Call
GlobeNewswire - Thu May 05, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that it will host its first quarter 2016 investor update call before the open of the U.S. financial markets on Thursday, May 12, 2016. Voyager management will host a conference call and live audio webcast at 8:30 a.m. ET the same day.
VYGR: 13.71 (-0.04)
Voyager Therapeutics Highlights Programs in Parkinson's Disease and ALS; Announces Expansion of CNS Pipeline at R&D Day
GlobeNewswire - Fri Apr 29, 7:00AM CDT
Top-Line Proof-of-Concept Clinical Data for Parkinson's Disease Program (VY-AADC01) Remains on Track for the Fourth Quarter of 2016
VYGR: 13.71 (-0.04)
Voyager Therapeutics (Nasdaq: VYGR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Mon Apr 25, 10:12AM CDT
What:
VYGR: 13.71 (-0.04), NDAQ: 69.62 (-0.18)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 13.71 (-0.04), OMED: 11.61 (-0.01), GSK: 42.93 (-0.13), BMY: 56.00 (+0.44), CELGZ: 1.20 (unch)
Voyager Therapeutics to Host R&D Day and Webcast on April 29, 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that the Company will host an R&D Day on Friday, April 29, 2016, from 8:30 a.m. - 11:00 a.m. ET in New York City.
VYGR: 13.71 (-0.04)
Voyager Therapeutics (VYGR) Jumps: Stock Rises 13.9%
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:15AM CDT
Voyager Therapeutics, Inc. (VYGR) shares rose almost 14% in the last trading session.
VYGR: 13.71 (-0.04), AMPH: 21.26 (+2.26)
Voyager Therapeutics Promotes Jeff Goater to Chief Financial Officer
GlobeNewswire - Tue Feb 02, 5:00PM CST
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former senior vice president of finance and business development, to chief financial officer. In this new role, Mr. Goater will be responsible for overseeing the company's financial strategy and planning, investor and public relations, corporate operations and business development.
VYGR: 13.71 (-0.04)
ProMIS Neurosciences Announces Formation of Prestigious Scientific Advisory and Business Advisory Boards
PRWeb - Tue Jan 26, 6:06AM CST
ProMIS™ Neurosciences, dedicated to development of precision medicine therapeutics for neurodegenerative diseases is pleased to announce the formation of its two key advisory boards to accelerate company development. ProMIS' first products will focus on more effective treatment of Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS). ProMIS Neurosciences is currently in the process of identifying and validating epitopes specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease.
VYGR: 13.71 (-0.04)
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 91.69 (+0.43), BMRN: 97.95 (-0.16), VYGR: 13.71 (-0.04), RPTP: 8.97 (unch), KNMD: (), SGMO: 4.62 (-0.08), BCLI: 2.52 (unch), CUR: 0.32 (+0.01)
Voyager Therapeutics Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Dec 17, 3:15PM CST
Initial public offering raised $72.7 million in net proceeds
VYGR: 13.71 (-0.04)
5 Biggest Losers from the Fed Rate Hike
Swarup Gupta - Zacks Investment Research - Thu Dec 17, 12:07PM CST
While markets greeted the news with cheer, worries can be felt below the surface.
MG: 24.09 (-0.21), CXO: 122.77 (-1.25), VYGR: 13.71 (-0.04), EGN: 52.27 (-0.41), SM: 33.24 (-1.31)
(0)
(0)Scroll down for more posts ▼